|
|
Gut. 1997 September; 41(3): 366–370. | PMCID: PMC1891485 |
Intravenous immunoglobulin therapy for severe Clostridium
difficile colitis J Salcedo, S Keates, C Pothoulakis, M Warny, I Castagliuolo, J LaMont, and C Kelly Section of Gastroenterology, Boston University School of Medicine, Massachusetts, USA. Background—Many individuals have serum antibodies
against Clostridium difficile toxins. Those with an
impaired antitoxin response may be susceptible to recurrent, prolonged,
or severe C difficile diarrhoea and colitis. Aims—To examine whether treatment with intravenous
immunoglobulin might be effective in patients with severe
pseudomembranous colitis unresponsive to standard antimicrobial therapy. Patients—Two patients with pseudomembranous
colitis not responding to metronidazole and vancomycin were given
normal pooled human immunoglobulin intravenously (200-300 mg/kg). Methods—Antibodies against C
difficile toxins were measured in nine immunoglobulin
preparations by ELISA and by cytotoxin neutralisation assay. Results—Both patients responded quickly as shown
by resolution of diarrhoea, abdominal tenderness, and distension. All
immunoglobulin preparations tested contained IgG against C
difficile toxins A and B by ELISA and neutralised the cytotoxic
activity of C difficile toxins in vitro at IgG
concentrations of 0.4-1.6 mg/ml. Conclusion—Passive immunotherapy with
intravenous immunoglobulin may be a useful addition to antibiotic
therapy for severe, refractory C difficile colitis. IgG
antitoxin is present in standard immunoglobulin preparations and
C difficile toxin neutralising activity is evident at IgG
concentrations which are readily achieved in the serum by intravenous
immunoglobulin administration.
Keywords:
Clostridium difficile; toxin; diarrhoea; IgG; immunotherapy; antibiotic
The Full Text of this article is available as a PDF (152K). These references are in PubMed. This may not be the complete list of references from this article. - Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994 Jan 27;330(4):257–262. [PubMed]
- McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989 Jan 26;320(4):204–210. [PubMed]
- Bongaerts GP, Lyerly DM. Role of toxins A and B in the pathogenesis of Clostridium difficile disease. Microb Pathog. 1994 Jul;17(1):1–12. [PubMed]
- Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988 Jan;1(1):1–18. [PubMed]
- Lyerly DM, Lockwood DE, Richardson SH, Wilkins TD. Biological activities of toxins A and B of Clostridium difficile. Infect Immun. 1982 Mar;35(3):1147–1150. [PubMed]
- Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, Cosentini E, Feil W, Schiessel R, LaMont JT, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest. 1995 May;95(5):2004–2011. [PubMed]
- Triadafilopoulos G, Pothoulakis C, O'Brien MJ, LaMont JT. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology. 1987 Aug;93(2):273–279. [PubMed]
- Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, Johnson JL. Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun. 1990 Feb;58(2):480–488. [PubMed]
- Kelly CP, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, LaMont JT, Pothoulakis C. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest. 1994 Mar;93(3):1257–1265. [PubMed]
- Triadafilopoulos G, Pothoulakis C, Weiss R, Giampaolo C, Lamont JT. Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Gastroenterology. 1989 Nov;97(5):1186–1192. [PubMed]
- von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M. Cloning of Clostridium difficile toxin B gene and demonstration of high N-terminal homology between toxin A and B. Med Microbiol Immunol. 1990;179(5):271–279. [PubMed]
- Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature. 1995 Jun 8;375(6531):500–503. [PubMed]
- Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, Mann M, Aktories K. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem. 1995 Jun 9;270(23):13932–13936. [PubMed]
- Kelly CP. Immune response to Clostridium difficile infection. Eur J Gastroenterol Hepatol. 1996 Nov;8(11):1048–1053. [PubMed]
- Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology. 1992 Jan;102(1):35–40. [PubMed]
- Nakamura S, Mikawa M, Nakashio S, Takabatake M, Okado I, Yamakawa K, Serikawa T, Okumura S, Nishida S. Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol. 1981;25(4):345–351. [PubMed]
- Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, Bartlett JG. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis. 1983 Jul;148(1):93–100. [PubMed]
- Aronsson B, Granström M, Möllby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection. 1985 May–Jun;13(3):97–101. [PubMed]
- Aronsson B, Granström M, Möllby R, Nord CE. Enzyme-linked immunosorbent assay (ELISA) for antibodies to Clostridium difficile toxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea. J Immunol Methods. 1983 Jun 10;60(3):341–350. [PubMed]
- Bacon AE, 3rd, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis. 1994 Apr;18(4):205–209. [PubMed]
- Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991 Apr;118(4 ():633–637. [PubMed]
- Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis. 1993 Jun;16 Suppl 4:S239–S244. [PubMed]
- Warny M, Vaerman JP, Avesani V, Delmée M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994 Feb;62(2):384–389. [PubMed]
- Kelly CP, Pothoulakis C, Vavva F, Castagliuolo I, Bostwick EF, O'Keane JC, Keates S, LaMont JT. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother. 1996 Feb;40(2):373–379. [PubMed]
- Pothoulakis C, Barone LM, Ely R, Faris B, Clark ME, Franzblau C, LaMont JT. Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem. 1986 Jan 25;261(3):1316–1321. [PubMed]
- Medich DS, Lee KK, Simmons RL, Grubbs PE, Yang HC, Showalter DP. Laparotomy for fulminant pseudomembranous colitis. Arch Surg. 1992 Jul;127(7):847–853. [PubMed]
- Morris LL, Villalba MR, Glover JL. Management of pseudomembranous colitis. Am Surg. 1994 Jul;60(7):548–552. [PubMed]
- Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995 Apr;38(4):350–354. [PubMed]
- Trudel JL, Deschênes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum. 1995 Oct;38(10):1033–1038. [PubMed]
- Bender BS, Bennett R, Laughon BE, Greenough WB, 3rd, Gaydos C, Sears SD, Forman MS, Bartlett JG. Is Clostridium difficile endemic in chronic-care facilities? Lancet. 1986 Jul 5;2(8497):11–13. [PubMed]
- McFarland LV. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. Am J Infect Control. 1995 Oct;23(5):295–305. [PubMed]
- Schwab R, Walters CA, Weksler ME. Host defense mechanisms and aging. Semin Oncol. 1989 Feb;16(1):20–27. [PubMed]
- Weksler ME. Immune senescence. Ann Neurol. 1994;35(Suppl):S35–S37. [PubMed]
- Corthier G, Muller MC, Wilkins TD, Lyerly D, L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun. 1991 Mar;59(3):1192–1195. [PubMed]
- Kim PH, Iaconis JP, Rolfe RD. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun. 1987 Dec;55(12):2984–2992. [PubMed]
- Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun. 1991 Jun;59(6):2215–2218. [PubMed]
- Tjellström B, Stenhammar L, Eriksson S, Magnusson KE. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet. 1993 Mar 13;341(8846):701–702. [PubMed]
- Hassett J, Meyers S, McFarland L, Mulligan ME. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis. 1995 Jun;20 Suppl 2:S266–S268. [PubMed]
- Pirofsky B, Campbell SM, Montanaro A. Individual patient variations in the kinetics of intravenous immune globulin administration. J Clin Immunol. 1982 Apr;2(2 Suppl):7S–14S. [PubMed]
- Pothoulakis C, LaMont JT, Eglow R, Gao N, Rubins JB, Theoharides TC, Dickey BF. Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J Clin Invest. 1991 Jul;88(1):119–125. [PubMed]
|